Home › NCT06433310

Understanding the Efficacy of Dietary Supplement on Fungal Mycobiota in Healthy Volunteers: A Pilot Study

Who can join

Ages 18 and older · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* Male or female adults over the age of 18 years

Exclusion Criteria:

* History of a diagnosis of any gastrointestinal condition, such as inflammatory bowel syndrome or disease
* Antibiotic usage within the past two weeks
* Antifungal usage within the past month
* Allergy to L-Phenylalanine or individuals with phenylketonuria (PKU)
* Adults taking medications known to interact with L-phenylalanine supplements, such as Monoamine Oxidase Inhibitors (MOAI), L-DOPA, and some antipsychotic drugs (complete and extensive drug list will be provided to interested participants during screening)
* Pregnant or nursing women

About the study

The purpose of this study is to explore how the dietary supplement L-Phenylalanine affects the production of the metabolite phenylpropionic acid (PPA) and changes fungal populations of the gut microbiome.

What is being tested

• L-Phenylalanine 500 mg Veg Capsule product (drug)

Sponsor: Weill Medical College of Cornell University · Participants: 20 · Started: Oct 17, 2024

Contact the study team

• Emilia T Vignogna, BS · Phone: 505-259-4995
• Tsering D Sherpa-Ngima, BSc · Phone: 929-328-9571

Official record on ClinicalTrials.gov — NCT06433310

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.